ISRCTN77828247已完成不适用
BiphentinEffects in attention deficit hyperactivity disorder (ADHD) Drivers: a randomised, placebo controlled, crossover study of multilayer-release (MLR) methylphenidate on driving performance in adult ADHD patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male or non-pregnant, non-nursing female patients at the age of 18 years or greater with a valid driver's license and at least six months of driving experience with driving activity at least twice per week
- •2. Patients must have a childhood history consistent with ADHD and must meet the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria for ADHD, inattentive or combined based on clinician assessment using multiple informants and a structured interview
- •3. Patients must be being treated with methylphenidate at the time of study entry. Either long-acting or short-acting formulations of methylphenidate are valid for study inclusion. Both the investigator and patient must rate satisfaction with treatment as satisfied or greater using a four-point ordinal scale (0 = unsatisfied, 1 = somewhat satisfied, 2 = satisfied, 3 = very satisfied)
- •4. In the case of women of childbearing potential, demonstration of a negative blood or urine pregnancy test at study entry or within seven days prior to study entry, and the use of a reliable method of contraception such as oral contraceptive, two barrier methods, a barrier method plus a spermicidal agent, female surgical sterilisation or abstinence
- •5. Patients who are mentally and physically competent to provide informed consent, and who have signed a form indicating their informed consent
- •6. Patients who are able and willing to comply with the study protocol
- •7. Patients who can be contacted by telephone at times specified by the protocol and who are able to return to the hospital or clinic for protocol specified visits and evaluations, including two weekends at the University of Guelph for the Driving Simulator
排除标准
- •1. Patients with a true allergy to methylphenidate or amphetamines, history of serious adverse reactions to methylphenidate or be known to be non-responsive to methylphenidate treatment. Non-response is defined as methylphenidate use at various doses for a period of at least four weeks at each dose with little or no clinical benefit.
- •2. Patients with a history of seizures, strokes, epilepsy, migraine headaches, glaucoma, thyrotoxicosis, tachyarrhythmias or severe angina pectoris or have serious or unstable medical illness, such as asthma, diabetes or seizures
- •3. Patients with elevated blood pressure, defined as any values above 90 mmHg diastolic and 150 mmHg systolic
- •4. Patients with a high risk of experiencing Simulator Adaptation Syndrome (SAS: a.k.a. Simulator Sickness)
- •5. Patients who are currently receiving guanethidine, pressor agents, monoamine oxidase [MAO] inhibitors, coumarin anticoagulants, anticonvulsants (e.g. phenobarbitol, phenytoin, primidone), phenylbutazone, tricyclic antidepressants (imipramine, desipramine), selective serotonin reuptake inhibitors (SSRIs) or herbal remedies (e.g. Effalux, valerian or melatonin)
- •6. Patients with a history of disorders of the sensory organs, particularly deafness or profound mental retardation
- •7. Patients with a diagnosis of schizophrenia, schizoaffective disorder, primary affective disorder, schizotypal personality, major depression, bipolar disorder, generalized anxiety, substance abuse, borderline personality disorder, antisocial personality or another unstable psychiatric condition requiring treatment, as assessed by a structured interview
- •8. Patients who are currently receiving any investigational drug, or have received an investigational drug in the previous month
- •9. Patients who are currently known or suspected to be abusing drugs or alcohol
研究者
相似试验
已完成
3 期
Aripiprazle in ADHD and ODDAttention deficit/hyperactivity disorder.Attention deficit/hyperactivity disorderIRCT20160530028182N6Sanandaj University of Medical Sciences76
已完成
2 期
Effect of treatment of attention deficit hyperactivity disorder (ADHD) with and without routine treatment of constipation on improvement of clinical symptoms in patients with functional constipatioConstipationIRCT20120215009014N222Hamedan University of Medical Sciences80
已完成
1 期
Effects of Using Betahistine to Treat Adults With Attention Deficit Hyperactivity DisorderAttention Deficit Disorder With HyperactivityNCT00829881P2D, Inc.16
已完成
2 期
ERP Based Single-dose Predictions of StimulantsAttention Deficit Hyperactivity DisorderNCT02695355Ostfold Hospital Trust87
已完成
2 期
Bupropion in the treatment of adult ADHDIRCT201302201556N51Tehran University of Medical Sciences40